Blood Protein Disorders
Showing 1 - 9 of 9
Multiple Myeloma, Multiple Myeloma in Relapse, Tumors Trial (Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide)
Not yet recruiting
- Multiple Myeloma
- +8 more
- Belantamab Mafodotin-Blmf
- +3 more
- (no location specified)
Oct 13, 2022
Multiple Myeloma, Tumors, Tumor, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- +7 more
- Belantamab Mafodotin-Blmf
- +3 more
- (no location specified)
Oct 11, 2022
Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)
Active, not recruiting
- Multiple Myeloma
- +19 more
- CYNK-001
-
Denver, Colorado
- +8 more
May 24, 2022
Multiple Myeloma, Tumors, Tumors, Plasma Cell Trial (Belantamab Mafodotin-Blmf, Daratumumab, Lenalidomide)
Not yet recruiting
- Multiple Myeloma
- +7 more
- Belantamab Mafodotin-Blmf
- +3 more
- (no location specified)
Mar 4, 2022
Coagulation in Post-partum Hemorrhage by Thromboelastography
Unknown status
- Coagulation Defect; Puerperal
- +3 more
-
Paris, FranceHopital Trousseau
Jul 9, 2018
Pulmonary Edemas, Blood Protein Disorders Trial in Rochester (RBC transfusion of 5 days or less storage age, RBC transfusion of
Completed
- Pulmonary Edemas
- Blood Protein Disorders
- RBC transfusion of 5 days or less storage age
- RBC transfusion of conventional storage age
-
Rochester, MinnesotaMayo Clinic
Jan 27, 2012